GANX - NASDAQ

Gain Therapeutics, Inc.

Gain Therapeutics, Inc.

GANXยทNASDAQ

$1.88

+4.7%
HealthcareBiotechnology

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$79.98M
EPS-0.6100
P/E Ratio-3.07
Earnings Date08/06/2026
Gain Therapeutics, Inc.

Gain Therapeutics, Inc. Fair Value Envelope

GANX ยท NASDAQ

Our analysis suggests that GANX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.875, this represents a potential HIDDEN relative to our calculated worth for Gain Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $1.875

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$138.6M
+ Cash & Equivalents$20.8M
Firm Value-$117.7M
- Debt$732.1K
Equity Value-$118.5M
/ Shares Outstanding35,948,606B
DCF Value-$3
OVERVALUED BY 276%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$18.9M
-$19.3M
-$19.8M
-$20.2M
-$20.7M
-$21.1M
-$21.6M
-$22.1M
-$22.6M
-$23.1M
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$18.9M
-$19.3M
-$19.8M
-$20.2M
-$20.7M
-$21.1M
-$21.6M
-$22.1M
-$22.6M
-$23.1M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$17.5M
-$16.6M
-$15.7M
-$14.9M
-$14.1M
-$13.3M
-$12.6M
-$11.9M
-$11.3M
-$10.7M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your GANX research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.